Previous 10 | Next 10 |
Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA PR Newswire SAN DIEGO , Nov. 18, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focu...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Heron Therapeutics to Present at Upcoming Investor Conferences PR Newswire SAN DIEGO , Nov. 11, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing be...
Heron Therapeutics, Inc. (HRTX) Q3 2021 Results Earnings Conference Call November 03, 2021, 04:15 PM ET Company Participants David Szekeres - Executive Vice President, Chief Operating Officer Barry Quart - Chief Executive Officer and Chairman of the Board John Poyhonen - President and Chief C...
Heron Therapeutics (NASDAQ:HRTX): Q3 GAAP EPS of -$0.51 beats by $0.10. Revenue of $23.23M (+16.3% Y/Y) misses by $2.28M. Shares -1.15%. Press Release As of September 30, 2021, Heron had cash, cash equivalents and short-term investments of $202.8 million, compared to $208.5 mil...
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate Updates - ZYNRELEF® net product sales of $2.1 million in its first quarter of launch with 160 unique accounts already purchasing ZYNRELEF an...
Heron Therapeutics (NASDAQ:HRTX) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, after market close. The consensus EPS Estimate is -$0.60 and the consensus Revenue Estimate is $25.51M (+27.7% Y/Y). In October, Seeking Alpha contributor Biologics believes that the...
Heron Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 3, 2021 PR Newswire SAN DIEGO , Oct. 28, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the ...
Biotech stocks can be volatile to the extreme. Former high-flying stocks can crash on a bad clinical outcome, regulatory review, or new competitor on the market. The interesting part, though, is that some former star biotech stocks can, on occasion, regain their momentum. Beaten-down biotec...
After setbacks with the FDA, Heron finally launched Zynrelef in July with a constricted label to market. I believe Zynrelef might struggle in its first few quarters on the market. Heron is looking to broaden Zynrelef’s label with supplementary studies. In addition, the company ...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 PR Newswire SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company...
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...